HME Business

  • Home
  • Topics
    • COVID-19
    • Accreditation
    • Competitive Bidding
    • DME Pharmacy
    • Legislative
    • Mobility
    • Oxygen
    • Pain Management
    • Retail
    • Sales and Marketing
    • Sleep Therapy
    • Software/IT
  • News
  • Resources
    • Whitepapers
    • Buyers Guide
    • DME Associations
  • Podcasts
  • Request Media Kit
  • Webinars
  • Digital Edition
  • Events
    • FUTURE Conference
  • Awards
  • Advertise
  • Subscribe

Philips Respironics Dispels Direct Sales Rumors

November 30, 2008 by HME Business

Philips Respironics has distributed a letter to its HME provider customers stating that it in no way plans on directly selling products to patients.

“While it’s true that Philips offers consumer products, our core products in sleep and home respiratory are prescribed medical devices that require specialized care to help ensure effective therapy and compliance,” reads the letter, which is signed by new Philips Respironics CEO Donald Spence. “We will continue to work to provide solutions to providers and clinicians that expand the home healthcare channel.”

The letter attributes the rumor to misinformation being spread by Philips Respironics’ competitors. It also sought to address possible confusion regarding two of its programs, Supply Direct and EncoreAnywhere.

The letter asserts that Supply Direct is a drop ship service that lets providers order OSA replacement supplies and have them shipped directly to patients. “This program was developed for and with the input of our customers to help them focus on patient care, while reducing costs and inventory investments,” the statement reads.

EncoreAnywhere lets various caregivers use a secure web portal to gather, access and share patient sleep therapy compliance data and information. “This system is intended to provide a lower cost, more timely and accurate methodology for monitoring patient acceptance to their therapy over manually intensive legacy alternatives,” the letter reads. “It also provides a lower cost when changing prescriptions in the field.”

Related Articles Read More >

HME Business Webinar: Growing Your DME Maternity Business
The Sept. 15 webinar is free to attend.
VieMed Reports Record Q2 Results Driven by Ventilation Growth
The company’s sleep therapy and maternal health segments also grew.
Wound Care Association Urges Public Comments on CY 2027 Medicare Physician Fee Schedule
Comments are due by Sept. 14.
New Study Examines Medicare Advantage Prior Authorization Denials, Successful Appeals
KFF analysis showed appeals are often successful, but not often used.

Get the free newsletter

Home Healthcare Softare

Subscribe to HME Business for industry & product news, trends and resources.
HME Business Directory
HME Podcasts
HME Business
  • Mobility Management
  • Senior Housing News
  • Home Health Care News
  • Skilled Nursing News
  • Hospice News
  • Behavioral Health Business
  • About HME Business
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search HME Business

  • Home
  • Topics
    • COVID-19
    • Accreditation
    • Competitive Bidding
    • DME Pharmacy
    • Legislative
    • Mobility
    • Oxygen
    • Pain Management
    • Retail
    • Sales and Marketing
    • Sleep Therapy
    • Software/IT
  • News
  • Resources
    • Whitepapers
    • Buyers Guide
    • DME Associations
  • Podcasts
  • Request Media Kit
  • Webinars
  • Digital Edition
  • Events
    • FUTURE Conference
  • Awards
  • Advertise
  • Subscribe